Navigation Links
Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at AUA Annual Meeting

surable tumor lesions, treatment with CB7630 resulted in partial radiological responses (as measured by the RECIST criteria) in 11 patients (55%), with 7 patients demonstrating ongoing stable disease and 3 patients experienced regressing bone disease. Individual patients treated with CB7630 also experienced improvement in pain and a reduction in opioid use.

Currently 19 (63%) of the 30 patients in the Phase I/II trial remain on study and are continuing to be treated with CB7630. Of the 15 patients in the Phase I portion of the trial, 9 patients (60%) are still receiving treatment with CB7630, with the average patient having received the drug for over 9.2 months and with 4 patients having received the drug for over 12 months.

Dr. Arie S. Belldegrun, M.D., FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology, said, "The clinical data on abiraterone continues to demonstrate strong evidence of the antitumor activity of the drug in CRPC patients. CB7630 has the potential to be used by both urologists who treat patients with second line hormonal therapies and by medical oncologists who treat patients in the second line chemotherapy setting; therefore, we are pleased to be able to present, for the first time, the clinical data on abiraterone to the urology community." Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, added, "We are pleased to be able to present the clinical data from this CB7630 trial at AUA. We look forward to continuing to provide updates on these ongoing trials at future cancer conferences and greatly look forward to the continued development of CB7630 in both the second line hormone therapy and second line chemotherapy settings."

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630,
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
3. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
7. Prana Biotechnology Presents New Key Findings on PBT2
8. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:8/21/2014)... -- CVS Caremark Corporation (NYSE: CVS ) announced ... payable in connection with its previously announced cash tender offers ... any and all of its 6.250% Senior Notes due 2027 ... maximum amount of its 6.125% Senior Notes due 2039, 5.750% ... (collectively, the "Maximum Tender Offer Notes" and together with the ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis ... three independent members to its Board of Directors, ... experience of the company, a leading licensed producer ... . Internationally, Bedrocan has 13 years, experience in ... in seven countries, including Canada. ...
(Date:8/21/2014)... 2014  SI-BONE, Inc. ( San Jose, California ... use of the iFuse Implant System, ® a ... the sacroiliac (SI) joint, announced that Priority Health ( ... Lumbar Fusion Medical Policy No. 91590-R4 providing positive coverage ... states that the fusion procedure, which employs the iFuse ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... 29, 2011  Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased ... in 2012 through the development and sales of its ... management of medical conditions. In 2011, Solos Endoscopy consummated ... in debt for the Company. The signed settlement agreement ...
... Today, Zacks Equity Research discusses the Pharma & Biotech, ... Human Genome Sciences Inc. (Nasdaq: HGSI ... and Perrigo Company (Nasdaq: PRGO ). ... synopsis of today,s Industry Outlook is presented below. The ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 2Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 3Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo 4
(Date:8/22/2014)... Teen substance abuse has long been major issue ... adults never receive the professional treatment they need. To ... Troubled Teens Columbus helpline was established to provide a ... and alcohol dependencies . , By calling ... can speak directly to a representative who can offer ...
(Date:8/22/2014)... 22, 2014 Drug and alcohol ... the years, substance abuse has claimed thousands of lives ... OH is providing hope for teenagers who are seeking ... helpline is designed to provide adolescents and their parents ... find the best youth rehab facility to meet their ...
(Date:8/22/2014)... Dr Murray Grossan was interviewed for an ... In the October 2014 issue of Bottom Line Personal magazine, ... method of treating snoring, and in some cases Obstructive Sleep ... of all adults snore occasionally, and about 25% do it ... passages in the back of the throat tend to sag ...
(Date:8/22/2014)... August 22, 2014 According to ... System and Adaptive Cruise Control (ACC) System Market ... Forecasts 2014 - 2019", published by MarketsandMarkets, classifies ... Market in terms of volume and value. The ... years as well as covers review of the ...
(Date:8/21/2014)... Dallas, TX (PRWEB) August 22, 2014 ... proportion of reimbursement for medical expenses, the Chinese ... with its scale presenting a CAGR of 19.2% ... products are three product segments of orthopedic instruments ... bulk with 36.9% market share in 2013. , ...
Breaking Medicine News(10 mins):Health News:New Helpline in Columbus Assists Troubled Teen Find Youth Rehab 2Health News:Substance Abuse Helpline Provides Hope for Teens & Parents in Brunswick, OH 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 2Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 3Health News:China Orthopedic Instrument Industry Report, 2014-2017 Now Available at ChinaMarketResearchReports.com 4
... the star had a miscarriage in 2005 . ,Pregnancy ... they tied the knot in September 2005, and now Lesley Guynes ... in fact become pregnant, but she lost the baby. ... her own. Demi and Ashton have been trying (to have a ...
... rights group PETA has commended Sir Paul McCartney for his ... ,The former Beatle, who has supported cancer charities ... 1998, recently revealed that he is planning to decline financial ... that he took the decision after discovering that a number ...
... have confirmed a long-standing belief that male circumcision can ... an international AIDS conference will be told next week ... International AIDS Society (IAS) conference to be held in ... represented a major development in HIV prevention. ...
... alarming depletion of ground water levels in the country and ... water table. ,The Central Groundwater Board has ... level at various places across the country and identified about ... score, a senior official said. ,"The constant mining ...
... left-handers, natural lefties who have switched over to right hand ... their brains are organized, and how hard particular regions ... in such peoples brains continue to retain characteristics of a ... righty. ,"The question now is, 'do converts suffer ...
... Novartis AG has been given the green light from the European ... still no access to its American counterpart. ... European Medicines Agency came soon after Novartis said it would ... due to a request for more safety data. ...
Cached Medicine News:Health News:Male Circumcision can Cut HIV Infection, Studies Show 2Health News:Groundwater Levels Depleting Alarmingly in India 2Health News:Converting Left-hander to Right-hander also Changes the Brain 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: